HC Wainwright & Co. Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.
HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.